N
NK:IO
Developing technologies to improve cancer treatment
About NK:IO
NK IO is a pioneering biotechnology company focused on developing innovative NK cell and small molecule therapies by leveraging the innate immune system. The company operates in the biopharmaceutical sector, targeting both anti-tumor responses and long-term pathogen infections. NK IO's core business model revolves around producing large quantities of NK cells on demand, which represents a novel approach with significant therapeutic potential. The company serves clients in the healthcare and pharmaceutical industries, including hospitals, research institutions, and biotech firms. NK IO generates revenue through the development, licensing, and commercialization of its proprietary therapies. The company also engages in strategic partnerships and collaborations to advance its research and development efforts.
Source: Dealroom company dataAt a glance
- Founded
- 2020
- Headquarters
- London, United Kingdom
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed7 investors entered at this stage
Parkwalk Advisors
Future Planet Capital
Imperial College London
Start Codon
Meltwind
Cancer Research Horizon
Cambridge Angels
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about NK:IO on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NK:IO on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.